Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Final Program in it's entirety - MyGirlsBlood
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Posters, Sunday and Monday<br />
Index of Poster Presenters cont’d<br />
08P09<br />
Same Prevalence but Low Response of Inhibitors <strong>in</strong> African<br />
Hemophiliacs Receiv<strong>in</strong>g Low Quantity of Factor Concentrates<br />
Saliou D, Aïssatou S, Moussa S, Bamar Guèye Y, Dièye T,<br />
Oumar AT, Sall A, Thiam D, Diakhaté L<br />
Service d’Hématologie, Université Cheikh Anta Diop, Dakar,<br />
Sénégal<br />
08P10<br />
Functional Characterization of Recomb<strong>in</strong>ant GlycoPEGylated<br />
FIX (40K PEG-rFIX) after Intravenous Adm<strong>in</strong>istration to<br />
Hemophilia B dogs (HB)<br />
Ezban M1 , Hansen L1 , Hermit M1 , Tranholm M1 , Østergård<br />
H1 , Nichols T2 1 2 Novo Nordisk A/S, Maaloev, Denmark University of North<br />
Carol<strong>in</strong>a, Chapel Hill, North Carol<strong>in</strong>a, U.S.A.<br />
08P11<br />
Levels of Transform<strong>in</strong>g Growth Factor- (Tgf- ) <strong>in</strong> Concentrates<br />
of Factor VIII Manufactured <strong>in</strong> Unc-Hemoderivados<br />
Farias F, Guglielmone H, Navarro D, Moya C and Vitali MS<br />
Area de Desarrollo de Productos y Procesos, UNC-<br />
Hemoderivados, Córdoba, Argent<strong>in</strong>a<br />
08P12<br />
Restoration of Thromb<strong>in</strong> Generation <strong>in</strong> Factor XI-Deficient<br />
Plasma Us<strong>in</strong>g a Factor XI Concentrate<br />
Feldman P, Hardway C<br />
Bio Products Laboratory, Elstree, U.K.<br />
08P13<br />
BERIATE®P <strong>in</strong> the Treatment of Patients with Hemophilia A:<br />
Update of a Long-Term Pharmacovigilance<br />
Klamroth R1 , Zimmermann R2 , Kurnik K3 , Holzhauer S4 ,<br />
Geist M5 1 2 Vivantes Kl<strong>in</strong>ikum Berl<strong>in</strong>, Germany, Kurpfalzkrankenhaus<br />
Heidelberg, Germany, 3Dr. v. Haunersches Childrens Hospital<br />
Munich, Germany, 4University Hospital Charité Berl<strong>in</strong>,<br />
Germany, 5CSL Behr<strong>in</strong>g, Germany<br />
08P14<br />
Update of a Long-Term Pharmacovigilance Project: Helixate®<br />
NexGen for the Treatment of Hemophilia A<br />
Oldenburg J1 , Petr<strong>in</strong>i P2 , Santagost<strong>in</strong>o E3 , Pab<strong>in</strong>ger I4 ,<br />
Geist M5 , Lenk H6 1 2 University Hospital Bonn, Germany, Karol<strong>in</strong>ska Sjukhuset<br />
Stockholm, Sweden, 3A. Bianchi Bonomi Haemophilia Center<br />
Milan, Italy, 4University Hospital Vienna, Germany, 5CSL Behr<strong>in</strong>g GmbH, Germany, 6University Hospital Leipzig,<br />
Germany<br />
52<br />
08P15<br />
An Accurate and Rout<strong>in</strong>ely Adapted Enzyme-L<strong>in</strong>ked<br />
Immunosorbent Assay for Type 2N von Willebrand Disease<br />
Diagnosis<br />
Caron C 1 , Ternisien C 2 , Wolf M 3 , Fress<strong>in</strong>aud E 3 , Veyradier A 3 ,<br />
Goudemand J 1 for the National Reference Centre on von<br />
Willebrand disease (CRMW)<br />
Hematology Department of 1 Lille, 2 Nantes, 3 Clamart, France<br />
08P16<br />
Prolonged Circulatory Half Life for rFVIIa After Conjugation<br />
to Hydroxyethy1 Starch<br />
Hey T and Hackett F<br />
Fresenius Kabi Deutschland GmbH, HESylation® Technology,<br />
Friedberg, Germany<br />
08P17<br />
Generation of Recomb<strong>in</strong>ant FVIII Purification Antibody of<br />
N8<br />
Hansen J, Bolt G, Kjærgaard K, Kristensen C, Steenstrup T<br />
Novo Nordisk A/S<br />
08P18<br />
Concept and Structure Model of Factor IX Album<strong>in</strong> Fusion<br />
Prote<strong>in</strong>s<br />
Horn C1 , Steuber H2 , Metzner H1 , Kuo W1 , Weimer T1 , Schulte<br />
S1 1 2 CSL Behr<strong>in</strong>g GmbH, Marburg, Germany, Institute of<br />
Biochemistry, University of Lübeck, Germany<br />
08P19<br />
Concept and Structure Model of Factor VIIa Album<strong>in</strong> Fusion<br />
Prote<strong>in</strong>s<br />
Horn C1 , Steuber H2 , Weimer T1 , Wormsbächer W1 , Lieb<strong>in</strong>g<br />
U1 , Kuo W1 1 2 CSL Behr<strong>in</strong>g GmbH, Marburg, Germany, Institute of<br />
Biochemistry, University of Lübeck, Germany<br />
08P20<br />
Therapy by rFVIIa (Novoseven) <strong>in</strong> Patients with Hemophilia<br />
A and Inhibitor: Factors Influenc<strong>in</strong>g Total Therapy<br />
Effectiveness<br />
Hulíková M 1<br />
, Hulíková J1 , Brabec P2 1Center of Haemostasis and Thrombosis, Hemo Medika,<br />
Košice, Slovakia, 2Institute of Biostatistics and Analyses,<br />
Masaryk University, Brno, Czech Republic<br />
08P21<br />
Transform<strong>in</strong>g Growth Factor Beta (TGF- 1) Content <strong>in</strong><br />
Octanate ® – Assessment and Methodological Issues<br />
Kannicht C, Fisseau C, Fuchs B<br />
Octapharma R&D, Molecular Biochemistry, Berl<strong>in</strong>, Germany